CBT-009

Myopia, also known as near-sightedness, can develop and progress in children and adolescents. Myopia is believed to be caused by an increase in eye length or by a change in corneal curvature, which directs light from distant objects to focus in front of the retina leading to blurred long-distance vision. Myopia with a refractive error of 0.50 to -6.00 diopters is considered to be low to moderate in severity, while myopia exceeding -6.00 diopters is considered higher in severity. Progressive myopia can also be due to an increase in the axial length of the eyeball, which heightens the risk for retinal degenerative changes and permanent vision loss.  Myopia is a leading cause of correctable vision loss with a potential for complications that can lead to blindness. If treated early, there is a potential for preventing myopia-associated complications.

阿托品是唯一被證明 been demonstrated to be consistently effective in slowing myopic progression. Currently, aqueous atropine eye drops are used in some 阿托品水滴眼液來治療近視患者，queous atropine eye drops are unstable and easily decompose into belladonna, 此外， 水性阿托品滴眼液不穩定，容易分解成顛茄、托品酸等物質，極大影響了這些滴眼液的功效和安全性。 

作為非水劑阿托品滴眼劑，CBT-009 與水劑阿托品不同的是， atropine by having higher stability, being preservative-free, and having higher 並且具有更高的生物利用度。